Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 1,080,000 shares, a drop of 50.9% from the February 13th total of 2,200,000 shares. Based on an average trading volume of 5,220,000 shares, the short-interest ratio is currently 0.2 days. Approximately 8.4% of the shares of the stock are sold short.

Moleculin Biotech Stock Performance

Moleculin Biotech stock traded down $0.03 during midday trading on Friday, reaching $1.13. The company’s stock had a trading volume of 492,587 shares, compared to its average volume of 6,934,791. Moleculin Biotech has a 52 week low of $0.40 and a 52 week high of $8.85. The business has a 50-day moving average price of $1.42 and a 200-day moving average price of $2.07.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MBRX. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com assumed coverage on shares of Moleculin Biotech in a report on Thursday. They issued a “sell” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Moleculin Biotech in a report on Monday, March 3rd.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.